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Abstract

1
We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against 2 meningococcal disease to children too old to receive the vaccine under the recently 3 introduced infant programme. Offering catch-up vaccination to increasingly older children is 4 less economically attractive because of declining disease burden. We estimate catch-up 5 vaccination of 1 year old children could be cost-effective, incremental on the infant 6 programme with a vaccine price of ≤£8 per dose. Extending vaccination to 2 year olds could 7 only be cost-effective (incremental on infant and 1 year old catch-up) with a vaccine price of 8 ≤£3 per dose and was not cost-effective in sensitivity analyses with more conservative 9 vaccine assumptions. Extending catch-up further to 3-4 year olds was not cost-effective.
10
Employing the current criteria for assessing vaccines, our models suggest that even with low 
19
The aim of this modelling study was to further investigate the cost-effectiveness of different 20 catch-up options, focusing not on children under 11 years, but on the birth cohorts after 21 infancy who experience the greatest disease burden, i.e. 1, 2 and 3-4 year olds.
23
Methods
24
We adapted the transmission dynamic mathematical and economic model used to inform the The cost-effectiveness of catch-up vaccination was considered incrementally on the existing 22 routine infant programme; we did not consider catch-up vaccination beyond 4 year olds 23 because our previous work (data not shown 3 ) had indicated this would not be cost-effective.
Future costs and benefits were discounted at 3.5% in the base case and analyses were . We also assessed the effect of using 3 1.5% discounting for cost and benefits, including family and network QALYs, assuming a 4 lower incidence and returning to the previous vaccine delivery cost of £7.50 per dose.
6
Results
7
In the base case model, catch-up vaccination of 1 year old children (83.8% uptake) with 8
Bexsero could be considered cost-effective, incremental on the existent routine infant 9 programme, if the vaccine could be procured at a low vaccine price, estimated at ≤£8 per 10 dose with a threshold of £20,000 per QALY gained (Table 1) . Extending the catch-up to 11 include 2 year olds (75.6% uptake) was less economically attractive, driven by the fact that respectively; 75.6% vaccine uptake in both year groups), and since disease incidence falls 20 further after this age, the same applies up to age 11 years.
22
Reducing the discounting for costs and benefits from 3.5% to 1.5% improves the incremental MenB disease. The base case model uses incidence over a seven year period to allow for 7 such future changes in disease, but this is higher than the low burden currently experienced.
8
Reducing the modelled number of annual cases of disease by a third, to more closely A strength of this work is that it builds upon a previously independently reviewed model 8 which was used to inform the infant recommendation for the use of Bexsero in the UK 11 .
9
There remains, however a considerable degree of uncertainty around many of the model 10 parameters and whilst surveillance data will help to reduce some of this uncertainty, it is still 11 too early in the programme to be able to revise any of the assumptions, for example of 12 vaccine effectiveness. To our knowledge this is the first study to consider the cost- potential herd effects generated through vaccinating this age group may not be large.
22
However, excluding any effect on carriage reduces the already low cost-effective vaccine would need to be done sufficiently early to afford protection to these children before the 8 winter peak in disease to maximise the benefit from immunisation. 
Conclusions
11
Based on the criteria currently used by JCVI our models suggest only catch-up vaccination 12 in 1 year old children could be recommended on economic grounds, incremental to the 13 existing infant programme, but only if the vaccine could be procured at a low cost. collection, data analysis, data interpretation, or writing of the report. HC will act as 7 guarantor. £188,500 £233,000 £4 NP 2,4+12 months + CU in 1-4y £190,300 £358,300 NP NP * 2,4+12 months + CU in 1y incremental on 2,4+12 months; 2,4+12 months + CU in 1-2y incremental on 2,4+12 months + CU in 1y etc. †Figures rounded to nearest 100. ‡Figures rounded to nearest £1. 
